Search

Your search keyword '"Hofheinz, Ralf"' showing total 1,021 results
Start Over Author "Hofheinz, Ralf"
1,021 results on '"Hofheinz, Ralf"'

4. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials

Author

Fokas, Emmanouil, Williams, Hannah, Diefenhardt, Markus, Lin, Sabrina, Qin, Li-Xuan, Piso, Pompiliu, Dapper, Hendrik, Germer, Christoph-Thomas, Grützmann, Robert, Tim Friede, J., Joshua Smith, J., Saltz, Leonard B., Wu, Abraham J., Weiser, Martin R., Omer, Dana, Ghadimi, Michael, Hofheinz, Ralf-Dieter, Garcia-Aguilar, Julio, and Rödel, Claus

Published
2024
Full Text
View/download PDF

5. Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study

Author

Li, Moying, Meindl-Beinker, Nadja M., Maenz, Martin, Betge, Johannes, Schulte, Nadine, Zhan, Tianzuo, Hofheinz, Ralf-Dieter, Vogel, Arndt, Angermeier, Stefan, Bolling, Claus, de Wit, Maike, Jakobs, Ralf, Karthaus, Meinolf, Stocker, Gertraud, Thuss-Patience, Peter, Leidig, Tobias, Bauer, Hans, Ebert, Matthias P., and Haertel, Nicolai

Published
2024
Full Text
View/download PDF

8. Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials

Author

Diefenhardt, Markus, Fleischmann, Maximillian, Martin, Daniel, Hofheinz, Ralf-Dieter, Piso, Pompiliu, Germer, Christoph-Thomas, Hambsch, Peter, Grützmann, Robert, Kirste, Simon, Schlenska-Lange, Anke, Ghadimi, Michael, Rödel, Claus, and Fokas, Emmanouil

Published
2023
Full Text
View/download PDF

11. Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal...

Author

Janjigian, Yelena Y., Van Laarhoven, Hanneke W.M., Rha, Sun Young, Kozlov, Vadim, Oh, Do-Youn, Gravina, Adriano, Rapatoni, Liane, Shoji, Hirokazu, Hofheinz, Ralf Dieter, Chen, Li-Tzong, Ford, Hugo, Chenard-Poirier, Maxime, de Giorgio-Miller, Victoria, Chang, Yi-Ting, Anadu, Obinna, and Lee, Jeeyun

Published
2025
Full Text
View/download PDF

12. Differential effects of sound interventions tuned to 432 Hz or 443 Hz on cardiovascular parameters in cancer patients: a randomized cross-over trial.

Author

Hohneck, Anna, Rodríguez, Ánxelo Maia, Weingärtner, Simone, Merx, Kirsten, Sarodnick, Felicitas, von Gagern, Fritjof, Mavratzas, Athanasios, Burkholder, Iris, Schumacher, Gerhard, Hofmann, Wolf-Karsten, and Hofheinz, Ralf-Dieter

Subjects
TUMOR treatment, VITAL signs, SADNESS, ARTERIAL diseases, DATA analysis, MUSIC therapy, STATISTICAL sampling, VISUAL analog scale, QUESTIONNAIRES, TREATMENT effectiveness, RANDOMIZED controlled trials, ANXIETY, DESCRIPTIVE statistics, CROSSOVER trials, CANCER pain, HEART beat, VASCULAR resistance, STATE-Trait Anxiety Inventory, PSYCHOLOGICAL stress, STATISTICS, DIASTOLIC blood pressure, CANCER patient psychology, COMPARATIVE studies, PULSE wave analysis, CANCER fatigue, PSYCHOLOGICAL tests, DATA analysis software, SYSTOLIC blood pressure, WELL-being
Abstract

Background: This study investigated whether a sound intervention tuned to 432 Hz (Hz) yields differential effects on cardiovascular parameters and psychological outcomes compared to 443 Hz, which is the concert pitch in German professional orchestras. Methods: Using a randomized cross-over design, patients with cancer were recruited to receive both a 15-minute sound intervention with a body monochord tuned to 432–443 Hz. Before (pre) and after (post) intervention, cardiovascular parameters were measured using the VascAssist2.0. In addition, visual analogue scales (VAS) for emotional well-being, anxiety, stress, pain and sadness were also assessed pre and post intervention. Results: 43 patients (8 male, 35 female) with a median age of 61 years (range 35–86) were included. Both interventions led to a significant reduction in heart rate with a more pronounced effect for 432 Hz (median reduction − 3 bpm (432 Hz) vs. median reduction − 1 bpm (443 Hz), p = 0.04). While heart rate variability was increased exclusively by 432 Hz (median increase + 3 ms, p = 0.01), both vascular resistance (median reduction − 5%, p = 0.008) and stiffness (median reduction %, p = 0.04) were significantly reduced by 432 Hz, which was not observed at 443 Hz. Nevertheless, these effects were not significantly different compared to 443 Hz. On the other hand, 432 Hz led to a reduced pulse wave velocity (median reduction − 0.5 m/s, p < 0.001), which was also significantly different compared to 443 Hz (p < 0.001). Improvement in VAS was observed for both groups, with significant increases in emotional well-being and reduction in fatigue, anxiety and stress for both intervention timepoints, although the majority showed no increased VAS scores even before the intervention (median values 0 for anxiety and stress). Conclusion: Sound interventions tuned to 432–443 Hz exert both positive effects in cancer patients. While psychological outcomes are improved by both interventions, 432 Hz leads to a more pronounced but not significantly different effect to 443 Hz on objective cardiovascular parameters, which reflect deeper relaxation. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

13. Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial

Author

Ebert, Matthias P, Meindl-Beinker, Nadja M, Gutting, Tobias, Maenz, Martin, Betge, Johannes, Schulte, Nadine, Zhan, Tianzuo, Weidner, Philip, Burgermeister, Elke, Hofheinz, Ralf, Vogel, Arndt, Angermeier, Stefan, Bolling, Claus, de Wit, Maike, Jakobs, Ralf, Karthaus, Meinolf, Stocker, Gertraud, Thuss-Patience, Peter, Leidig, Tobias, Gaiser, Timo, Kather, Jakob N, and Haertel, Nicolai

Published
2022
Full Text
View/download PDF

17. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

Author

Wen, Patrick Y, Stein, Alexander, van den Bent, Martin, De Greve, Jacques, Wick, Antje, de Vos, Filip Y F L, von Bubnoff, Nikolas, van Linde, Myra E, Lai, Albert, Prager, Gerald W, Campone, Mario, Fasolo, Angelica, Lopez-Martin, Jose A, Kim, Tae Min, Mason, Warren P, Hofheinz, Ralf-Dieter, Blay, Jean-Yves, Cho, Daniel C, Gazzah, Anas, Pouessel, Damien, Yachnin, Jeffrey, Boran, Aislyn, Burgess, Paul, Ilankumaran, Palanichamy, Gasal, Eduard, and Subbiah, Vivek

Published
2022
Full Text
View/download PDF

20. Arbeitsgruppen zu kolorektalen Tumoren der AIO, der ACO und der ARO – „past, present, and future“

Author

Hofheinz, Ralf, Arnold, Dirk, Fichtner-Feigl, Stefan, Fokas, Emmanouil, Folprecht, Gunnar, Geissler, Michael, Ghadimi, Michael, Hegewisch-Becker, Susanne, Heinemann, Volker, Kasper-Virchow, Stefan, Kubicka, Stefan, Modest, Dominik Paul, Piso, Pompilio, Reinacher-Schick, Anke, Rödel, Claus-Michael, Seufferlein, Thomas, Stein, Alexander, and Stintzing, Sebastian

Published
2022
Full Text
View/download PDF

22. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer

Author

Fokas, Emmanouil, Appelt, Ane, Glynne-Jones, Robert, Beets, Geerard, Perez, Rodrigo, Garcia-Aguilar, Julio, Rullier, Eric, Joshua Smith, J., Marijnen, Corrie, Peters, Femke P., van der Valk, Maxine, Beets-Tan, Regina, Myint, Arthur S., Gerard, Jean-Pierre, Bach, Simon P., Ghadimi, Michael, Hofheinz, Ralf D., Bujko, Krzysztof, Gani, Cihan, Haustermans, Karin, Minsky, Bruce D., Ludmir, Ethan, West, Nicholas P., Gambacorta, Maria A., Valentini, Vincenzo, Buyse, Marc, Renehan, Andrew G., Gilbert, Alexandra, Sebag-Montefiore, David, and Rödel, Claus

Published
2021
Full Text
View/download PDF

23. Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial

Author

Kosmala, Rebekka, Fokas, Emmanouil, Flentje, Michael, Sauer, Rolf, Liersch, Torsten, Graeven, Ullrich, Fietkau, Rainer, Hohenberger, Werner, Arnold, Dirk, Hofheinz, Ralf-Dieter, Ghadimi, Michael, Ströbel, Philipp, Staib, Ludger, Grabenbauer, Gerhard G., Folprecht, Gunnar, Kirste, Simon, Uter, Wolfgang, Gall, Christine, Rödel, Claus, and Polat, Bülent

Published
2021
Full Text
View/download PDF

25. Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer.

Author

Hofheinz, Ralf-Dieter, Arnold, Dirk, Borner, Markus, Eisterer, Wolfgang, Folprecht, Gunnar, Ghadimi, Michael, Graeven, Ullrich, Grünberger, Birgit, Hebart, Holger, Hegewisch-Becker, Susanna, Heinemann, Volker, Pritzkuleit, Ron, Rödel, Claus, Rumpold, Holger, Trarbach, Tanja, Maschmeyer, Georg, and Wörmann, Bernhard

Subjects
*RECTAL cancer, *NEOADJUVANT chemotherapy, *CHEMORADIOTHERAPY, *CANCER treatment, *IMMUNOTHERAPY
Abstract

This article briefly summarizes clinically relevant new aspects of the recently published German, Austrian, and Swiss Onkopedia guideline for the treatment of locally advanced rectal cancer. Main aspects comprise (i) the use of total neoadjuvant therapy for rectal cancers with high-risk features, (ii) treatment with neoadjuvant chemotherapy for patients with a low risk for local recurrence, (iii) immunotherapy using dostarlimab in patients with MSI high/dMMR rectal cancer, as well as (iv) the implementation of organ sparing treatment concepts. The availability of several evidence-based treatment options requires intensive discussion within the multidisciplinary team as well as dedicated information for patients about treatment goals, options, and risks of individual treatment approaches. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Immune Checkpoint Blockade Combined with AbnobaViscum ® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence.

Author

Schad, Friedemann, Thronicke, Anja, Hofheinz, Ralf-Dieter, Klein, Reinhild, Grabowski, Patricia, Oei, Shiao Li, Wüstefeld, Hannah, and Grah, Christian

Subjects
PROGRAMMED death-ligand 1, NON-small-cell lung carcinoma, RANDOMIZED controlled trials, OVERALL survival, IMMUNE checkpoint proteins
Abstract

Background: Recent advancements in cancer treatment have shown the potential of immune checkpoint blockade (ICB) plus Viscum album L. therapy in improving survival rates for patients with advanced or metastatic non-small-cell lung cancer (NSCLC). The objective of this study was to investigate factors associated with improved survival in NSCLC patients treated with a combination of ICB and abnobaViscum®. Methods: Patients with advanced or metastatic NSCLC from the accredited Network Oncology registry were included in this real-world data study adhering to ESMO-GROW criteria with ethics approval. Survival outcomes were compared between patients receiving ICB therapy alone versus those receiving combinational ICB plus abnobaViscum® therapy using Kaplan–Meier and multivariable Cox proportional hazard analysis. Results: Among 300 patients (median age 68 years; male/female ratio 1.19), 222 received ICB alone (CTRL group) and 78 received combinational therapy (COMB group). Overall survival was significantly prolonged in the COMB group by 7 months compared to CTRL (13.8 months vs. 6.8 months, p = 0.005) with a survival rate of 16.5% in the COMB group vs. 8.0% in the CTRL group. In programmed death-ligand 1 positive (≥1%) patients treated with first-line ICB, the addition of abnobaViscum® reduced the adjusted hazard of death by 75% (aHR: 0.25; 95%CI: 0.11–0.60, p = 0.02). Conclusions: The addition of abnobaViscum® to ICB is significantly associated with improved survival in patients with advanced or metastatic NSCLC patients, irrespective of age, stage, Eastern cooperative oncology group status, surgery, or radiation. Potential mechanisms include immune modulation, reduced primary ICB resistance, and tumor microenvironment modifications. The findings warrant further validation in randomized controlled trials or registry-based randomized controlled trials. Trial registration: The study was registered (DRKS00013335). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Tumor Response and Its Impact on Treatment Failure in Rectal Cancer: Does Intensity of Neoadjuvant Treatment Matter?

Author

Diefenhardt, Markus, Martin, Daniel, Fleischmann, Maximilian, Hofheinz, Ralf-Dieter, Ghadimi, Michael, Rödel, Claus, and Fokas, Emmanouil

Subjects
DATA analysis, RESEARCH funding, TREATMENT effectiveness, CANCER patients, DESCRIPTIVE statistics, RECTUM tumors, LONGITUDINAL method, ADJUVANT chemotherapy, COMBINED modality therapy, STATISTICS, TREATMENT failure, COMPARATIVE studies, TUMOR classification, DISEASE incidence
Abstract

Simple Summary: The response to neoadjuvant treatment in rectal cancer varies among patients, while the evidence of benefit from additional adjuvant chemotherapy, especially in patients with persistent tumor and/or lymph node metastases, is unclear. In our cohort study of 1778 patients, we showed that persistent tumor and/or lymph node metastasis after intensified neoadjuvant treatment, e.g., total neoadjuvant treatment (TNT), was not more strongly associated with an extensive risk of treatment failure (TF, local recurrence and/or distant metastasis) than after less intensive neoadjuvant treatment, e.g., 5-flurouracil-based chemoradiotherapy (5-FU CRT). These results may help clinicians to individualize their surveillance strategies, but do not provide an argument for adding additional chemotherapy in non-responders after TNT. Objectives: Additional adjuvant treatment in patients with rectal cancer with limited response to neoadjuvant treatment to mitigate their higher risk of treatment failure remains controversial. Methods: This is a post hoc analysis of a cohort study of 3 randomized phase 2 or 3 trials (CAO/ARO/AIO-94, -04, and -12 trial) that included 1948 patients with locally advanced rectal adenocarcinoma. After excluding patients with missing information, 1788 patients (1254 men and 524 women; median age: 62.6 years, age range: 19–84 years) were eligible. We analyzed the extent of tumor response and its association with the incidence of treatment failure after different neoadjuvant treatment approaches. Results: Tumor response was significantly enhanced with more intensive neoadjuvant treatment. After a median follow-up of 55 months for the entire cohort (IQR: 37 months–62 months), the incidence of treatment failure (TF) stratified by tumor response or post-neoadjuvant pathological outcome was not significantly affected by the intensity of neoadjuvant treatment, whereas the ypTNM stage was significantly associated with the risk of treatment failure. Conclusions: In this cohort study, we provide evidence that limited or no response to intensified neoadjuvant treatment protocols is not likely to be more strongly associated with an extensive risk of TF after 5-FU CRT+/− adjuvant chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Differential effects of sound interventions tuned to 432 Hz or 443 Hz on cardiovascular parameters in cancer patients: A randomized cross-over trial

Author

Hohneck, Anna, primary, Rodríguez, Ánxelo Maia, additional, Weingärtner, Simone, additional, Merx, Kirsten, additional, Sarodnick, Felicitas, additional, von Gagern, Fritjof, additional, Mavratzas, Athanasios, additional, Burkholder, Iris, additional, Schumacher, Gerhard, additional, Hofmann, Wolf-Karsten, additional, and Hofheinz, Ralf-Dieter, additional

Published
2024
Full Text
View/download PDF

34. Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction:A Network Meta-Analysis

Author

Ronellenfitsch, Ulrich, Friedrichs, Juliane, Barbier, Emilie, Bass, Gary A., Burmeister, Bryan, Cunningham, David, Eyck, Ben M., Grilli, Maurizio, Hofheinz, Ralf Dieter, Kieser, Meinhard, Kleeff, Jörg, Klevebro, Fredrik, Langley, Ruth, Lordick, Florian, Lutz, Manfred, Mauer, Murielle, Michalski, Christoph W., Michl, Patrick, Nankivell, Matthew, Nilsson, Magnus, Seide, Svenja, Shah, Manish A., Shi, Qian, Stahl, Michael, Urba, Susan, Van Lanschot, Jan, Vordermark, Dirk, Walsh, Thomas Noel, Ychou, Marc, Proctor, Tanja, Vey, Johannes A., Ronellenfitsch, Ulrich, Friedrichs, Juliane, Barbier, Emilie, Bass, Gary A., Burmeister, Bryan, Cunningham, David, Eyck, Ben M., Grilli, Maurizio, Hofheinz, Ralf Dieter, Kieser, Meinhard, Kleeff, Jörg, Klevebro, Fredrik, Langley, Ruth, Lordick, Florian, Lutz, Manfred, Mauer, Murielle, Michalski, Christoph W., Michl, Patrick, Nankivell, Matthew, Nilsson, Magnus, Seide, Svenja, Shah, Manish A., Shi, Qian, Stahl, Michael, Urba, Susan, Van Lanschot, Jan, Vordermark, Dirk, Walsh, Thomas Noel, Ychou, Marc, Proctor, Tanja, and Vey, Johannes A.

Abstract

Importance: The prognosis of patients with adenocarcinoma of the esophagus and esophagogastric junction (AEG) is poor. From current evidence, it remains unclear to what extent preoperative chemoradiotherapy (CRT) or preoperative and/or perioperative chemotherapy achieve better outcomes than surgery alone. Objective: To assess the association of preoperative CRT and preoperative and/or perioperative chemotherapy in patients with AEG with overall survival and other outcomes. Data Sources:Literature search in PubMed, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, ClinicalTrials.gov, and International Clinical Trials Registry Platform was performed from inception to April 21, 2023. Study Selection: Two blinded reviewers screened for randomized clinical trials comparing preoperative CRT plus surgery with preoperative and/or perioperative chemotherapy plus surgery, 1 intervention with surgery alone, or all 3 treatments. Only data from participants with AEG were included from trials that encompassed mixed histology or gastric cancer. Among 2768 initially identified studies, 17 (0.6%) met the selection criteria. Data Extraction and Synthesis: The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines were followed for extracting data and assessing data quality by 2 independent extractors. A bayesian network meta-analysis was conducted using the 2-stage approach. Main Outcomes and Measures: Overall and disease-free survival, postoperative morbidity, and mortality. Results:The analyses included 2549 patients (2206 [86.5%] male; mean [SD] age, 61.0 [9.4] years) from 17 trials (conducted from 1989-2016). Both preoperative CRT plus surgery (hazard ratio [HR], 0.75 [95% credible interval (CrI), 0.62-0.90]; 3-year difference, 105 deaths per 1000 patients) and preoperativ

Published
2024

36. Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials

Author

Ronellenfitsch, Ulrich, Jensen, Katrin, Seide, Svenja, Kieser, Meinhard, Schwarzbach, Matthias, Slanger, Tracy E., Burmeister, Bryan, Kelsen, David, Niedzwiecki, Donna, Piessen, Guillaume, Schuhmacher, Christoph, Urba, Susan, van de Velde, Cornelis, Ychou, Marc, Hofheinz, Ralf, and Lorenzen, Sylvie

Published
2019
Full Text
View/download PDF

37. Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A

Author

Burgermeister, Elke, Battaglin, Francesca, Eladly, Fagr, Wu, Wen, Herweck, Frank, Schulte, Nadine, Betge, Johannes, Härtel, Nicolai, Kather, Jakob N., Weis, Cleo-Aron, Gaiser, Timo, Marx, Alexander, Weiss, Christel, Hofheinz, Ralf, Miller, Ian S., Loupakis, Fotios, Lenz, Heinz-Josef, Byrne, Annette T., and Ebert, Matthias P.

Published
2019
Full Text
View/download PDF

38. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Author

Al-Batran, Salah-Eddin, Homann, Nils, Pauligk, Claudia, Goetze, Thorsten O, Meiler, Johannes, Kasper, Stefan, Kopp, Hans-Georg, Mayer, Frank, Haag, Georg Martin, Luley, Kim, Lindig, Udo, Schmiegel, Wolff, Pohl, Michael, Stoehlmacher, Jan, Folprecht, Gunnar, Probst, Stephan, Prasnikar, Nicole, Fischbach, Wolfgang, Mahlberg, Rolf, Trojan, Jörg, Koenigsmann, Michael, Martens, Uwe M, Thuss-Patience, Peter, Egger, Matthias, Block, Andreas, Heinemann, Volker, Illerhaus, Gerald, Moehler, Markus, Schenk, Michael, Kullmann, Frank, Behringer, Dirk M, Heike, Michael, Pink, Daniel, Teschendorf, Christian, Löhr, Carmen, Bernhard, Helga, Schuch, Gunter, Rethwisch, Volker, von Weikersthal, Ludwig Fischer, Hartmann, Jörg T, Kneba, Michael, Daum, Severin, Schulmann, Karsten, Weniger, Jörg, Belle, Sebastian, Gaiser, Timo, Oduncu, Fuat S, Güntner, Martina, Hozaeel, Wael, Reichart, Alexander, Jäger, Elke, Kraus, Thomas, Mönig, Stefan, Bechstein, Wolf O, Schuler, Martin, Schmalenberg, Harald, and Hofheinz, Ralf D

Published
2019
Full Text
View/download PDF

40. Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Pancreatic Cancer in Germany

Author

Lugnier, Celine, primary, Sommerlatte, Sabine, additional, Attenberger, Ulrike, additional, Beer, Ambros J., additional, Bentz, Martin, additional, Benz, Stefan R., additional, Birkner, Thomas, additional, Büntzel, Jens, additional, Ebert, Matthias P.A., additional, Fasching, Peter, additional, Fischbach, Wolfgang, additional, Fokas, Emmanouil, additional, Fricke, Birgit, additional, Hense, Helene, additional, Grohmann, Erich, additional, Hofheinz, Ralf-Dieter, additional, Hüppe, Dietrich, additional, Huster, Stefan, additional, Jahn, Patrick, additional, Klinkhammer-Schalke, Monika, additional, Knauf, Wolfgang, additional, Kraeft, Anna-Lena, additional, Maier, Bernd Oliver, additional, Marckmann, Georg, additional, Niegisch, Günter, additional, Otto, Lutz, additional, Pelzer, Uwe, additional, Piso, Pompiliu, additional, Rosenau, Henning, additional, Schmitt, Jochen, additional, Schoffer, Olaf, additional, Sehouli, Jalid, additional, Tannapfel, Andrea, additional, Wedding, Ulrich, additional, Wesselmann, Simone, additional, Winkler, Eva C., additional, Zimmermann, Tanja, additional, Wörmann, Bernhard, additional, Reinacher-Schick, Anke, additional, and Schildmann, Jan, additional

Published
2024
Full Text
View/download PDF

41. Gastroesophageal Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023

Author

Scheck, Magdalena K., primary, Ekmekciu, Ira, additional, Sommerhäuser, Greta, additional, Heise, Christian, additional, Mavroeidi, Ilektra Antonia, additional, Kunzmann, Volker, additional, Wege, Henning, additional, Reinacher-Schick, Anke, additional, Hofheinz, Ralf-Dieter, additional, Oliver Götze, Thorsten, additional, Lorenzen, Sylvie, additional, and Nieto, Alexander Edward, additional

Published
2024
Full Text
View/download PDF

42. Colorectal Cancer Highlights from the European Society for Medical Oncology Annual Meeting 2023

Author

Ekmekciu, Ira, primary, Nieto, Alexander Edward, additional, Scheck, Magdalena K., additional, Heise, Christian, additional, Mavroeidi, Ilektra Antonia, additional, Kunzmann, Volker, additional, Götze, Thorsten Oliver, additional, Wege, Henning, additional, Reinacher-Schick, Anke, additional, Lorenzen, Sylvie, additional, Hofheinz, Ralf-Dieter, additional, and Sommerhäuser, Greta, additional

Published
2024
Full Text
View/download PDF

43. Pancreatic, Hepatic, and Biliary Tract Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023

Author

Heise, Christian, primary, Nieto, Alexander Edward, additional, Scheck, Magdalena K., additional, Ekmekciu, Ira, additional, Sommerhäuser, Greta, additional, Reinacher-Schick, Anke, additional, Hofheinz, Ralf-Dieter, additional, Lorenzen, Sylvie, additional, Wege, Henning, additional, Kunzmann, Volker, additional, Götze, Thorsten Oliver, additional, and Mavroeidi, Ilektra Antonia, additional

Published
2024
Full Text
View/download PDF

45. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Luft, Alexander V., Karaseva, Nina A., Kowalyszyn, Rubén Dario, Hernandez, Carlos Alberto, Csoszi, Tibor, De Vita, Ferdinando, Pfeiffer, Per, Sugimoto, Naotoshi, Kocsis, Judit, Csilla, Andràs, Bodoky, Gyorgy, Garnica Jaliffe, Georgina, Protsenko, Svetlana, Madi, Ayman, Wojcik, Elzbieta, Brenner, Baruch, Folprecht, Gunnar, Sarosiek, Tomasz, Peltola, Katriina Johanna, Bono, Peter, Ayala, Hubert, Aprile, Giuseppe, Gerardo, Cardellino Giovanni, Huitzil Melendez, Fidel David, Falcone, Alfredo, Di Costanzo, Francesco, Tehfe, Moustapha, Mineur, Laurent, García Alfonso, Pilar, Obermannova, Radka, Senellart, Hélène, Petty, Russell, Samuel, Leslie, Acs, Peter Istvan, Hussein, Maen Abdelkarim, Nechaeva, Marina N., Erdkamp, F.L.G., Won, Elizabeth, Bendell, Johanna Chock, Gallego Plazas, Javier, Lorenzen, Sylvie, Melichar, Bohuslav, Escudero, Miguel Angel, Pezet, Denis, Phelip, Jean-Marc, Kaen, Diego Lucas, Reeves, James A. Jr, Longo Muñoz, Federico, Madhusudan, Srinivasan, Barone, Carlo, Fein, Luis Enrique, Gomez Villanueva, Angel, Hebbar, Mohamed, Prausova, Jana, Visa Turmo, Laura, Vidal Barrull, Joana, Yilmaz, Mette Karen Nytoft, Beny, Alex, Van Laarhoven, H.M.W., DiCarlo, Brian Anthony, Esaki, Taito, Fujitani, Kazumasa, Geboes, Karen, Geva, Ravit, Kadowaki, Shigenori, Leong, Stephen, Machida, Nozomu, Raj, Moses Sundar, Ramirez Godinez, Francisco Javier, Ruzsa, Agnes, Ford, Hugo, Lawler, William E., Maisey, Nicolas Robert, Petera, Jiri, Shacham-Shmueli, Einat, Sinapi, Isabelle, Yamaguchi, Kensei, Hara, Hiroki, Beck, Joseph Thaddeus, Błasińska-Morawiec, Maria, Villalobos Valencia, Ricardo, Alcindor, Thierry, Bajaj, Madhuri, Berry, Scott, Gomez, Christina Maria, Dammrich, Daniel, Patel, Ravindranath, Taieb, Julien, Ten Tije, A.J., Burkes, Ronald L., Cabanillas, Fernando, Firdaus, Irfan, Chua, Cynthia Coo, Hironaka, Shuichi, Hofheinz, Ralf-Dieter, Lim, Howard J., Nordsmark, Marianne, Piko, Bela, Verma, Udit, Wadsley, Jonathan, Yukisawa, Seigo, Gutiérrez Delgado, Francisco, Denlinger, Crystal S., Kallio, Raija, Pikiel, Joanna, Wojcik-Tomaszewska, Joanna, Brezden-Masley, Christine, Jang, Raymond Woo-Jun, Pribylova, Jana, Sakai, Daisuke, Bartoli, Maria Alejandra, Cats, A., Grootscholten, M.I., Dichmann, Robert Andrew, Hool, Hugo, Shaib, Walid, Tsuji, Akihito, Van den Eynde, Marc, Velez-Cortez, Hector, Asmis, Timothy R., Fuchs, Charles S, Shitara, Kohei, Di Bartolomeo, Maria, Lonardi, Sara, Al-Batran, Salah-Eddin, Van Cutsem, Eric, Ilson, David H, Alsina, Maria, Chau, Ian, Lacy, Jill, Ducreux, Michel, Mendez, Guillermo Ariel, Alavez, Alejandro Molina, Takahari, Daisuke, Mansoor, Wasat, Enzinger, Peter C, Gorbounova, Vera, Wainberg, Zev A, Hegewisch-Becker, Susanna, Ferry, David, Lin, Ji, Carlesi, Roberto, Das, Mayukh, and Shah, Manish A

Published
2019
Full Text
View/download PDF

48. RAMIRIS: Wirksamkeit von Ramucirumab plus FOLFIRI vs. Ramucirumab plus Paclitaxel bei Patienten mit fortgeschrittenem oder metastasiertem Adenokarzinom des Magens oder des gastroösophagealen Übergangs, die auf eine Erstlinientherapie progredient sind – eine randomisierte Phase-II/III-Studie der AIO

Author

Lorenzen, Sylvie, Goetze, Thorsten O, Dechow, Tobias, Goekkurt, Eray, Hofheinz, Ralf-Dieter, Möhler, Markus, Stahl, Michael, Thuss-Patience, Peter, Hinke, Axel, Herzer, Sascha, Pauligk, Claudia, and Al-Batran, Salah-Eddin

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results